Pfizer reported strong financial results for the second quarter of 2025, with revenue reaching $14.65 billion, surpassing estimates of $13.5 billion and marking a 10% year-over-year increase. Adjusted earnings per share (EPS) were $0.78, beating the estimated $0.58 and reflecting a 30% rise from the previous year. The company’s net income for the quarter was $2.91 billion, with reported EPS at $0.51. Pfizer raised its full-year 2025 adjusted EPS guidance to a range of $2.90 to $3.10, up from the previous forecast of $2.80 to $3.00, while maintaining its revenue guidance between $61 billion and $64 billion. The company attributed the improved outlook to ongoing cost-cutting measures and a weaker U.S. dollar. Pfizer is on track to achieve approximately $7.2 billion in net cost savings by the end of 2027, contributing to operating margin expansion. These results and guidance revisions were well received by the market, with Pfizer’s shares rising in pre-market trading.